Epizyme Inc (EPZM) 19.91 $EPZM
Epizyme Granted Patent Covering Diagnosis and Treatment of Cancers Associated with EZH2 Mutation
PR Newswire - Tue Apr 08, 6:30AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,691,507 with claims that cover the identification of patients carrying EZH2 oncogenic mutations as candidates for treatment with EZH2 inhibitors. EZH2 is a histone methyltransferase (HMT) that can become oncogenic due to genetic alterations and cause non-Hodgkin lymphoma and solid tumors. The patent, entitled "Inhibitors of Human EZH2 and Methods of Use Thereof," expires in 2033.
Epizyme (EPZM): Moving Average Crossover Spotted - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 9:02AM CDT
Epizyme (EPZM): Moving Average Crossover Spotted
What You Ought To Know About Celgene's Deal-Making Magic
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 05, 5:30PM CST
Celgene , the biotech giant best known for its $4 billion a year myeloma drug Revlimid, has been among the most active in making deals with young biotech companies. In January, Celgene made its latest deal, handing over $50 million to cozy up to...
Epizyme, Inc. to Present at 34th Annual Cowen and Company Health Care Conference on March 3, 2014
PR Newswire - Fri Feb 28, 7:30AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation at the Cowen and Company 34th Annual Health Care Conference.
Epizyme Announces 2013 Operating and Financial Results and Provides 2014 Guidance
PR Newswire - Thu Feb 27, 3:00PM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced 2013 operating and financial results and provided 2014 guidance.
Epizyme Achieves Lead Candidate Selection Milestone in GSK Collaboration, Earning $2 Million Milestone
PR Newswire - Thu Feb 27, 7:00AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the lead candidate selection milestone for one of the histone methyltransferase (HMT) targets in the company's collaboration with GSK. This achievement triggers a milestone payment of $2 million and follows the announcement in January 2014 of the achievement of a development candidate milestone for another of the HMT targets in the collaboration, which earned Epizyme a $4 million milestone payment.
Epizyme Announces Publication of Preclinical Data Demonstrating Clinical Candidate EPZ-6438 as Potent and Selective Inhibitor of EZH2 in Genetically Defined Non-Hodgkin Lymphoma
PR Newswire - Fri Feb 21, 7:11AM CST
Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the publication of data from preclinical studies of the company's clinical candidate EPZ-6438 (E7438), a potent and selective small-molecule inhibitor of EZH2, a histone methyltransferase (HMT). Oncogenic mutations in EZH2 occur in a subset of patients with non-Hodgkin lymphoma (NHL), implicating EZH2 as a therapeutic target in these patients. This research, published online today and in the April issue of the journal Molecular Cancer Therapeutics, provides a preclinical description of EPZ-6438, which Epizyme is developing in partnership with Eisai for the treatment of EZH2 mutant-bearing NHL. The paper expands on data reported by the same authors in a poster presentation at the December 2012 American Society of Hematology (ASH) annual meeting.
Epizyme, Inc.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:57PM CST
The following issues have been halted by IIROC:
Epizyme, Inc. to Report Fourth Quarter and Year-End 2013 Financial Results on February 27, 2014
PR Newswire - Wed Feb 19, 3:30PM CST
Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Thursday, February 27, 2014, at 4:30 p.m. ET to report fourth quarter and year-end 2013 financial results.
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 14, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Myeloproliferative Disorders - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 11, 9:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rhjv83/myeloproliferative) has announced the addition of the "Myeloproliferative Disorders - Pipeline Review, H2 2013" report to their offering. 'Myeloproliferative Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myeloproliferative Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myeloproliferative Disorders. Scope - A snapshot of the global therapeutic scenario for Myeloproliferative Disorders. - A review of the Myeloproliferative Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Myeloproliferative Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Myeloproliferative Disorders Overview Therapeutics Development Clinical Stage Products Early Stage Products Myeloproliferative Disorders - Products under Development by Companies Myeloproliferative Disorders - Products under Investigation by Universities/Institutes Myeloproliferative Disorders - Companies Involved in Therapeutics Development Myeloproliferative Disorders - Therapeutics Assessment Triapine - Drug Profile givinostat - Drug Profile ganetespib - Drug Profile KB-004 - Drug Profile gandotinib - Drug Profile EPZ-5676 - Drug Profile ON-044580 - Drug Profile Small Molecules To Inhibit JAK2 For Myeloproliferative Neoplasms - Drug Profile Kinase Inhibitors for Oncology - Drug Profile Small Molecule To Inhibit JAK2 For Myeloproliferative Disorder - Drug Profile AG-120 - Drug Profile CPL-407-22 - Drug Profile Jak2 Inhibitors - Drug Profile Featured News & Press Releases Companies Mentioned Eli Lilly and Company Genentech, Inc. Merck & Co., Inc. Nanotherapeutics, Inc. Synta Pharmaceuticals Corp. Italfarmaco S.p.A. Celon Pharma Sp. z o.o. Agios Pharmaceuticals, Inc. Onconova Therapeutics, Inc. KaloBios Pharmaceuticals, Inc. EpiZyme, Inc. For more information visit http://www.researchandmarkets.com/research/rh...liferative About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Epizyme Announces Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock
PR Newswire - Tue Feb 11, 7:00AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative personalized therapeutics for patients with genetically defined cancers, today announced that, following the initial closing of its recent public offering on February 10, 2014, the underwriters for the offering exercised in full their option to purchase 673,901 additional shares of common stock from the Company at the public offering price of $29.25 per share, less underwriting discounts. The sale of the additional shares is expected to close on or about February 12, 2014, subject to customary closing conditions.
3 Biotech Stocks Rising on Big Volume
at The Street - Tue Feb 11, 5:00AM CST
Keep these biotech stocks trading on unusual volume on your radar.
Epizyme, Inc. to Present at Upcoming Conferences in February
PR Newswire - Fri Feb 07, 7:00AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced it will present a company overview at the following conferences in February:
Epizyme prices public offering at USD29.25 per share
M2 - Thu Feb 06, 6:32AM CST
US-based biopharmaceutical company Epizyme Inc (NasdaqGS:EPZM) said on Wednesday that it has priced its public offering of 4,492,679 common shares at USD29.25 per share before underwriting discounts.
Epizyme Announces Pricing of Public Offering of Common Stock
PR Newswire - Wed Feb 05, 7:00AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative personalized therapeutics for patients with genetically defined cancers, today announced the pricing of its underwritten public offering of 4,492,679 shares of its common stock at a price of $29.25 per share before underwriting discounts. Epizyme is selling 3,000,000 shares of its common stock in this offering, and certain existing stockholders are selling 1,492,679 shares of common stock in this offering. Epizyme will not receive any proceeds from the sale of shares by the selling stockholders. In addition, Epizyme has granted to the underwriters a 30-day option to purchase up to 673,901 additional shares of common stock, if any, at the public offering price, less the underwriting discount.
Epizyme Announces Proposed Public Offering of Common Stock
PR Newswire - Mon Feb 03, 5:51AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative personalized therapeutics for patients with genetically defined cancers, today announced that it has commenced an underwritten public offering of 4,192,679 shares of its common stock. The offering is expected to consist of 3,000,000 shares to be offered by Epizyme and 1,192,679 shares to be offered by existing stockholders. Epizyme will not receive any proceeds from the sale of shares by the selling stockholders. In addition, Epizyme intends to grant the underwriters a 30-day option to purchase up to 628,901 shares of common stock.
Epizyme Heads Back to Wall Street, Plans $140M Raise
Ben Fidler, The Motley Fool - Motley Fool - Mon Jan 27, 10:59AM CST
Epizyme saw its stock jump up a few weeks ago after hitting a milestone in its big partnership with Celgene. Now it plans to use some of that momentum to raise some more cash from public investors. On Monday morning, Cambridge, MA-based...
J.P. Morgan Confab Focus Reminds Us Upside Remains In Biotech
at The Street - Fri Jan 17, 2:30PM CST
Biotechnology stocks have been front and center this week amidst the J.P. Morgan Healthcare conference, the big conference held in San Francisco each January where so many companies reveal important outlooks for the year and important pipeline...
Biotech Stock Roundup: Intercept Pharma Grabs the Limelight - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jan 15, 8:31AM CST
An eventful week for the biotech sector with several outperformers like Intercept, Epizyme, Sangamo and Pharmacyclics.
Epizyme Granted Patent Covering Diagnosis and Treatment of Cancers Associated with EZH2 Mutation
PR Newswire - Tue Apr 08, 6:30AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,691,507 with claims that cover the identification of patients carrying EZH2 oncogenic mutations as candidates for treatment with EZH2 inhibitors. EZH2 is a histone methyltransferase (HMT) that can become oncogenic due to genetic alterations and cause non-Hodgkin lymphoma and solid tumors. The patent, entitled "Inhibitors of Human EZH2 and Methods of Use Thereof," expires in 2033.
Epizyme (EPZM): Moving Average Crossover Spotted - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 9:02AM CDT
Epizyme (EPZM): Moving Average Crossover Spotted
What You Ought To Know About Celgene's Deal-Making Magic
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 05, 5:30PM CST
Celgene , the biotech giant best known for its $4 billion a year myeloma drug Revlimid, has been among the most active in making deals with young biotech companies. In January, Celgene made its latest deal, handing over $50 million to cozy up to...
Epizyme, Inc. to Present at 34th Annual Cowen and Company Health Care Conference on March 3, 2014
PR Newswire - Fri Feb 28, 7:30AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation at the Cowen and Company 34th Annual Health Care Conference.
Epizyme Announces 2013 Operating and Financial Results and Provides 2014 Guidance
PR Newswire - Thu Feb 27, 3:00PM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced 2013 operating and financial results and provided 2014 guidance.
Epizyme Achieves Lead Candidate Selection Milestone in GSK Collaboration, Earning $2 Million Milestone
PR Newswire - Thu Feb 27, 7:00AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the lead candidate selection milestone for one of the histone methyltransferase (HMT) targets in the company's collaboration with GSK. This achievement triggers a milestone payment of $2 million and follows the announcement in January 2014 of the achievement of a development candidate milestone for another of the HMT targets in the collaboration, which earned Epizyme a $4 million milestone payment.
Epizyme Announces Publication of Preclinical Data Demonstrating Clinical Candidate EPZ-6438 as Potent and Selective Inhibitor of EZH2 in Genetically Defined Non-Hodgkin Lymphoma
PR Newswire - Fri Feb 21, 7:11AM CST
Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the publication of data from preclinical studies of the company's clinical candidate EPZ-6438 (E7438), a potent and selective small-molecule inhibitor of EZH2, a histone methyltransferase (HMT). Oncogenic mutations in EZH2 occur in a subset of patients with non-Hodgkin lymphoma (NHL), implicating EZH2 as a therapeutic target in these patients. This research, published online today and in the April issue of the journal Molecular Cancer Therapeutics, provides a preclinical description of EPZ-6438, which Epizyme is developing in partnership with Eisai for the treatment of EZH2 mutant-bearing NHL. The paper expands on data reported by the same authors in a poster presentation at the December 2012 American Society of Hematology (ASH) annual meeting.
Epizyme, Inc.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:57PM CST
The following issues have been halted by IIROC:
Epizyme, Inc. to Report Fourth Quarter and Year-End 2013 Financial Results on February 27, 2014
PR Newswire - Wed Feb 19, 3:30PM CST
Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Thursday, February 27, 2014, at 4:30 p.m. ET to report fourth quarter and year-end 2013 financial results.
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 14, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Myeloproliferative Disorders - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 11, 9:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rhjv83/myeloproliferative) has announced the addition of the "Myeloproliferative Disorders - Pipeline Review, H2 2013" report to their offering. 'Myeloproliferative Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myeloproliferative Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myeloproliferative Disorders. Scope - A snapshot of the global therapeutic scenario for Myeloproliferative Disorders. - A review of the Myeloproliferative Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Myeloproliferative Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Myeloproliferative Disorders Overview Therapeutics Development Clinical Stage Products Early Stage Products Myeloproliferative Disorders - Products under Development by Companies Myeloproliferative Disorders - Products under Investigation by Universities/Institutes Myeloproliferative Disorders - Companies Involved in Therapeutics Development Myeloproliferative Disorders - Therapeutics Assessment Triapine - Drug Profile givinostat - Drug Profile ganetespib - Drug Profile KB-004 - Drug Profile gandotinib - Drug Profile EPZ-5676 - Drug Profile ON-044580 - Drug Profile Small Molecules To Inhibit JAK2 For Myeloproliferative Neoplasms - Drug Profile Kinase Inhibitors for Oncology - Drug Profile Small Molecule To Inhibit JAK2 For Myeloproliferative Disorder - Drug Profile AG-120 - Drug Profile CPL-407-22 - Drug Profile Jak2 Inhibitors - Drug Profile Featured News & Press Releases Companies Mentioned Eli Lilly and Company Genentech, Inc. Merck & Co., Inc. Nanotherapeutics, Inc. Synta Pharmaceuticals Corp. Italfarmaco S.p.A. Celon Pharma Sp. z o.o. Agios Pharmaceuticals, Inc. Onconova Therapeutics, Inc. KaloBios Pharmaceuticals, Inc. EpiZyme, Inc. For more information visit http://www.researchandmarkets.com/research/rh...liferative About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Epizyme Announces Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock
PR Newswire - Tue Feb 11, 7:00AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative personalized therapeutics for patients with genetically defined cancers, today announced that, following the initial closing of its recent public offering on February 10, 2014, the underwriters for the offering exercised in full their option to purchase 673,901 additional shares of common stock from the Company at the public offering price of $29.25 per share, less underwriting discounts. The sale of the additional shares is expected to close on or about February 12, 2014, subject to customary closing conditions.
3 Biotech Stocks Rising on Big Volume
at The Street - Tue Feb 11, 5:00AM CST
Keep these biotech stocks trading on unusual volume on your radar.
Epizyme, Inc. to Present at Upcoming Conferences in February
PR Newswire - Fri Feb 07, 7:00AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced it will present a company overview at the following conferences in February:
Epizyme prices public offering at USD29.25 per share
M2 - Thu Feb 06, 6:32AM CST
US-based biopharmaceutical company Epizyme Inc (NasdaqGS:EPZM) said on Wednesday that it has priced its public offering of 4,492,679 common shares at USD29.25 per share before underwriting discounts.
Epizyme Announces Pricing of Public Offering of Common Stock
PR Newswire - Wed Feb 05, 7:00AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative personalized therapeutics for patients with genetically defined cancers, today announced the pricing of its underwritten public offering of 4,492,679 shares of its common stock at a price of $29.25 per share before underwriting discounts. Epizyme is selling 3,000,000 shares of its common stock in this offering, and certain existing stockholders are selling 1,492,679 shares of common stock in this offering. Epizyme will not receive any proceeds from the sale of shares by the selling stockholders. In addition, Epizyme has granted to the underwriters a 30-day option to purchase up to 673,901 additional shares of common stock, if any, at the public offering price, less the underwriting discount.
Epizyme Announces Proposed Public Offering of Common Stock
PR Newswire - Mon Feb 03, 5:51AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative personalized therapeutics for patients with genetically defined cancers, today announced that it has commenced an underwritten public offering of 4,192,679 shares of its common stock. The offering is expected to consist of 3,000,000 shares to be offered by Epizyme and 1,192,679 shares to be offered by existing stockholders. Epizyme will not receive any proceeds from the sale of shares by the selling stockholders. In addition, Epizyme intends to grant the underwriters a 30-day option to purchase up to 628,901 shares of common stock.
Epizyme Heads Back to Wall Street, Plans $140M Raise
Ben Fidler, The Motley Fool - Motley Fool - Mon Jan 27, 10:59AM CST
Epizyme saw its stock jump up a few weeks ago after hitting a milestone in its big partnership with Celgene. Now it plans to use some of that momentum to raise some more cash from public investors. On Monday morning, Cambridge, MA-based...
J.P. Morgan Confab Focus Reminds Us Upside Remains In Biotech
at The Street - Fri Jan 17, 2:30PM CST
Biotechnology stocks have been front and center this week amidst the J.P. Morgan Healthcare conference, the big conference held in San Francisco each January where so many companies reveal important outlooks for the year and important pipeline...
Biotech Stock Roundup: Intercept Pharma Grabs the Limelight - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jan 15, 8:31AM CST
An eventful week for the biotech sector with several outperformers like Intercept, Epizyme, Sangamo and Pharmacyclics.
